AVOLYNT, INC.
Biotech · Private
remogliflozin etabonate, an SGLT2 inhibitor therapeutic for primary biliary cholangitis
- Grants
- $226K
- 1 award
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- 7
- 0 granted · 7 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20212022
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase I · Remogliflozin Etabonate Effect on Primary Biliary Cholangitis | $226,375 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2739 | MIXEDLCMEDIA LLC | — | — |
| 2740 | LUCEOME BIOTECHNOLOGIES, LLC | — | — |
| 2741 | PROTEIN ENGINES LLC | — | — |
| 2742 | AVOLYNT, INC. | — | — |
| 2743 | TRIA BIOSCIENCE CORPORATION | — | — |
| 2744 | HINGEZ THERAPEUTICS, INC. | — | — |
| 2745 | BLUE RIDGE BIOSCIENCES, LLC | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Patents
- Use Of SGLT2 Inhibitors To Treat Primary Billiary Cholangitisapplication
- Use Of SGLT2 Inhibitors To Treat Primary Sclerosing Cholangitisapplication
- Method For Treating Primary Sclerosing Cholangitisapplication
- Use Of SGLT2 Inhibitors To Treat Primary Sclerosing Cholangitisapplication
- Method For Treating Primary Sclerosing Cholangitisapplication
- Compositions And Methods For Treating Metabolic Diseaseapplication
- Use Of SGLT2 Inhibitors To Treat Primary Biliary Cholangitisapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.